Kancera Financial Statements From 2010 to 2024
| KAN Stock | SEK 1.06 0.02 1.85% |
Check Kancera AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kancera AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Kancera financial statements analysis is a perfect complement when working with Kancera AB Valuation or Volatility modules.
Kancera |
Kancera AB Company Return On Asset Analysis
Kancera AB's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kancera AB Return On Asset | -0.27 |
Most of Kancera AB's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kancera AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kancera AB has a Return On Asset of -0.2736. This is 96.87% lower than that of the Healthcare sector and 98.84% lower than that of the Biotechnology industry. The return on asset for all Sweden stocks is 95.43% higher than that of the company.
Kancera AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kancera AB's current stock value. Our valuation model uses many indicators to compare Kancera AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kancera AB competition to find correlations between indicators driving Kancera AB's intrinsic value. More Info.Kancera AB is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kancera AB's earnings, one of the primary drivers of an investment's value.About Kancera AB Financial Statements
Kancera AB shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Kancera AB investors may analyze each financial statement separately, they are all interrelated. The changes in Kancera AB's assets and liabilities, for example, are also reflected in the revenues and expenses on on Kancera AB's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.